We celebrate AI breakthroughs for their headline numbers – sensitivity, specificity, benchmark-beating accuracy – and then wonder why they fail to change outcomes at scale. The real challenge is rarely the model; it is the messy, human system that must adopt it.
Context (signal)
Researchers have published a multi-centre study of an AI pipeline called PANDA that detects pancreatic lesions from standard (non‑contrast) CT scans. Reported results show high sensitivity (~92.9%) and specificity (~99.9%) and the model found lesions that were missed by radiologists in a clinical roll‑out across emergency, outpatient and screening settings.
What this means for enterprise architecture and health systems
1) Clinical utility ≠ benchmark performance
High sensitivity and specificity on retrospective datasets are necessary but not sufficient. The true metric for health systems is impact on patient outcomes and care pathways: earlier curative interventions, fewer missed diagnoses, and acceptable false‑positive workups that don’t overwhelm scarce oncology services. Any vendor or in‑house team must convert “can the model detect” into “will the model improve outcomes given my capacity and referral pathways.”
2) Integration is the harder engineering problem
PACS/RIS/HIS integration, HL7/FHIR mappings, DICOM compliance, and lifecycle management of models in production are the unsung tasks. Architectures must support:
– Seamless intercept of CTs (non‑contrast) without changing radiology workflows.
– Explainability and confidence scores surfaced in radiology viewers.
– Audit trails and versioning (who saw what, when, and which model version made the call).
– Real‑time alerts with clinician-in-the-loop escalation for actionable positives.
3) Deployment strategy: edge, cloud or hybrid
Non‑contrast CT detection lowers the bar for input data, but compute and connectivity realities matter. In metros a cloud inference service may suffice; for district hospitals and remote diagnostic centres, lightweight edge inference or asynchronous batch processing with periodic syncs is more realistic. Design for intermittent connectivity and prioritise small, well‑tested on‑device models for low‑bandwidth settings.
4) Governance, liability and validation
Regulatory clearance, local validation, and medico‑legal frameworks must be in place before clinical adoption. Models are not “one and done” – they drift as scanner models, acquisition protocols, and population mixes change. An MLOps pipeline for monitoring performance, re‑training with local labelled data, and automatic rollback is mandatory.
5) Equity, bias and workforce impact
A model trained predominantly on data from tertiary centres risks lower performance in community hospitals. False negatives are deadly; false positives consume resources. AI should augment radiologists (prioritise cases, second read) rather than replace them. Training programs and clear SOPs are needed so clinicians trust and appropriately act on AI findings.
A practical roadmap for CTOs and hospital leaders
– Start with a tight pilot focused on a single use case (e.g., incidental non‑contrast chest CTs screened opportunistically for pancreatic lesions), defined endpoints (time‑to‑diagnosis, stage shift), and clinician adoption metrics.
– Insist on local validation before clinical use; collect and label cases prospectively to measure real‑world sensitivity, specificity, and workflow impact.
– Build integration adapters for PACS/HIS, include explainability overlays, and instrument logging for audit and compliance.
– Plan capacity – if detection improves, downstream imaging, oncology and surgery services will see increased demand; budget for that.
– Adopt an MLOps strategy: monitoring, data capture, governance, and a clear re‑training cadence.
Why this matters to India (and Northeast India)
The technical virtue of PANDA – using standard, non‑contrast CT – is also its strategic strength in low‑resource settings: it leverages existing imaging infrastructure without requiring contrast agents or specialized protocols. For regions with limited specialist coverage (including parts of Northeast India), a hub‑and‑spoke model combining AI at district centres and specialist review via tele‑radiology can raise early detection rates. But to succeed here, solutions must be frugal (low compute footprint), privacy‑preserving (local inference or strong encryption), and validated on local populations.
Takeaways
– Treat high retrospective performance as a signal, not a guarantee.
– Design for integration, monitoring and local validation from day one.
– Align AI deployment with care‑path capacity and clinician workflows.
– In low‑resource geographies, prioritise edge/hybrid architectures and pragmatic pilot designs.
Closing thought
AI that detects disease is only meaningful when it becomes part of a resilient clinical system – one that preserves trust, scales sustainably, and measurably improves lives.
About the Author Sanjeev Sarma is the Founder Director of Webx Technologies Private Limited, a leading Technology Consulting firm with over two decades of experience. A seasoned technology strategist and Chief Software Architect, he specializes in Enterprise Software Architecture, Cloud-Native Applications, AI-Driven Platforms, and Mobile-First Solutions. Recognized as a “Technology Hero” by Microsoft for his pioneering work in e-Governance, Sanjeev actively advises state and central technology committees, including the Advisory Board for Software Technology Parks of India (STPI) across multiple Northeast Indian states. He is also the Managing Editor for Mahabahu.com, an international journal. Passionate about fostering innovation, he actively mentors aspiring entrepreneurs and leads transformative digital solutions for enterprises and government sectors from his base in Northeast India.
